E-XR Development Pipeline of Explorable Environments

Author(s):  
Jakub Flotyński
Keyword(s):  
Author(s):  
Tanay Dalvi ◽  
Bhaskar Dewangan ◽  
Rudradip Das ◽  
Jyoti Rani ◽  
Suchita Dattatray Shinde ◽  
...  

: The most common reason behind dementia is Alzheimer’s disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.


MedChemComm ◽  
2015 ◽  
Vol 6 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Inés González-Gil ◽  
Debora Zian ◽  
Henar Vázquez-Villa ◽  
Silvia Ortega-Gutiérrez ◽  
María L. López-Rodríguez

The current status of the LPA1receptor and its ligands in the drug development pipeline is reviewed.


2021 ◽  
Author(s):  
Heinz-Josef Schmitt

Enterovirus A71 (EV A71) (genus enterovirus, family pircornaviridae) causes benign vesicular lesions on skin (hand, foot and mouth disease, HFMD) and mucous membranes of the mouth (herpangina), and also severe to life-threatening infections of the brain, the heart, and other internal organs. Disease outbreaks in the Asia-Pacific region regularly involve thousands of children <5 years resulting in many deaths. Such outbreaks are caused by specific EV genotypes that vary by time and place. While there are various promising and innovative options for treatment in development, none are licensed to date. Immunoglobulins may be beneficial through virus neutralization and modulation of the inflammatory response by the host. In China, 3 different highly efficacious and safe vaccines are commercially available; however, none are licensed outside the country. Roughly half a dozen vaccines are in the development pipeline, with some using innovative approaches and trying to broaden strain coverage.


Vaccine ◽  
2016 ◽  
Vol 34 (26) ◽  
pp. 2863-2864 ◽  
Author(s):  
Birgitte K. Giersing ◽  
Kayvon Modjarrad ◽  
David C. Kaslow ◽  
Jean-Marie Okwo-Bele ◽  
Vasee S. Moorthy

Author(s):  
Marion E. Glick

Public relations is not just sending out a press release or invitations to an event. It is the profession of managing communications between an organization and its audiences. As a public relations professional, you develop and execute communications programs that consider and support such corporate goals as reputation, the selling of products or services, recruitment of employees, or encouragement of investments. You can do this as an in-house professional at the company or as a client service if you work in an agency. If you want to apply your science journalism skills to corporate public relations, they will be highly prized by pharmaceutical, biotechnology, medical device, technology, and related companies. You not only comprehend the facts about environmental, physical, or life sciences, you can make them understandable to others. You can accurately and efficiently translate the function and value of a product or service to audiences as varied as customers, stockholders, regulators, and journalists, all of whom have different levels of scientific understanding. But being savvy about the scientific process and journalism is not enough. You also have to understand the business. Yes, it is about the money or, rather, commercial decision-making. To do your job well, you must know how the company makes money, who runs the show, who are the customers, how the business will grow, how it is regulated, and who are the existing or potential partners and competitors. And you should know these aspects as well as you know the company's research and development pipeline, patents, or marketed products or services. As someone who made the transition from managing public relations about medical research for academic and governmental organizations to that of Pharmaceuticals and biotechs, I can say that mastering “the business stuff” is possible. Many excellent resources are available, but start by skimming business magazines, checking out Hoover's Online (www.hoovers.com), and reading the annual reports of your company or clients. To manage corporate public relations, you need a program, which is the blueprint that captures the vision and the means to obtain it. Programs are very structured and have goals, objectives, strategies, and measurable tactics to achieve them.


2020 ◽  
Vol 31 (11) ◽  
pp. 2277-2286
Author(s):  
Axel Treu ◽  
Julia Kokesch-Himmelreich ◽  
Kerstin Walter ◽  
Christoph Hölscher ◽  
Andreas Römpp

Sign in / Sign up

Export Citation Format

Share Document